Invokana

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
012320132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Canagliflozin (Invokana) is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor that was first introduced in 2013 for… (More)
Is this relevant?
2016
2016
Sodium–glucose cotransporter 2 (SGLT2) inhibitors have been associated with euglycemic diabetic ketoacidosis (eDKA). All reports… (More)
Is this relevant?
2016
2016
BACKGROUND Renal reabsorption of 1,5-anhydroglucitol (AG) is competitively inhibited by elevated glucose and leads to depleted… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 4
  • figure 3
Is this relevant?
2015
2015
Canagliflozin (Invokana) is an innovative treatment for type 2 diabetes mellitus (DM) approved in a new class acknowledged as… (More)
Is this relevant?
Review
2015
Review
2015
  • The Medical letter on drugs and therapeutics
  • 2015
A significant decrease in cardiovascular mortality has been reported with use of the SGLT2 inhibitor empagliflozin (Jardiance) to… (More)
Is this relevant?
2014
2014
Acetylcholinesterase (AChE) is a primary target for Alzheimer's therapy while recently sodium glucose cotransporter 2 (SGLT2) has… (More)
Is this relevant?
Review
2014
Review
2014
Canagliflozin is an inhibitor of sodium-glucose cotransporters type 2 (SGLT2) that are present in renal tubules. This specific… (More)
Is this relevant?
Review
2013
Review
2013
Diabetes Mellitus is a chronic metabolic disease affecting wide range of people across the globe. In India the rate of subjects… (More)
Is this relevant?
Review
2013
Review
2013
volume 31 number 6 June 2013 nature biotechnology thiazolidinediones (TZDs). NICE requested additional evidence and said it will… (More)
Is this relevant?
Review
2013
Review
2013
  • The Medical letter on drugs and therapeutics
  • 2013
 
Is this relevant?